Literature DB >> 8182134

92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen.

M Ståhle-Bäckdahl1, M Inoue, G J Guidice, W C Parks.   

Abstract

Eosinophils are prominent in bullous pemphigoid (BP), and proteases secreted from these and other inflammatory cells may induce disruption of the basement membrane. We used in situ hybridization and immunohistochemistry to localize the sites of 92-kD gelatinase expression in BP lesions. In all samples (20/20), a strong signal for gelatinase mRNA was detected only in eosinophils and was most pronounced where these cells accumulated at the floor of forming blisters. No other cells were positive for enzyme mRNA. Both eosinophils and neutrophils, however, contained immunoreactive 92-kD gelatinase indicating that active expression occurred only in eosinophils. Degranulated eosinophils were also seen near blisters, and as demonstrated by gelatin zymography, immunoblotting, and ELISA, 92-kD gelatinase protein was prominent in BP blister fluid. No other gelatinolytic activity was specifically detected in BP fluid, and only small amounts of 92-kD gelatinase were present in suction blister fluids. As demonstrated in vitro, 92-kD gelatinase cleaved the extracellular, collagenous domain of recombinant 180-kD BP autoantigen (BP180, BPAG2, HD4, type XVII collagen), a transmembrane molecule of the epidermal hemidesmosome. Our results suggest that production and release 92-kD gelatinase by eosinophils contributes significantly to tissue damage in BP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182134      PMCID: PMC294314          DOI: 10.1172/JCI117196

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180.

Authors:  G J Giudice; D J Emery; L A Diaz
Journal:  J Invest Dermatol       Date:  1992-09       Impact factor: 8.551

2.  Expression of 92-kDa type IV collagenase mRNA by eosinophils associated with basal cell carcinoma.

Authors:  M Ståhle-Bäckdahl; B D Sudbeck; A Z Eisen; H G Welgus; W C Parks
Journal:  J Invest Dermatol       Date:  1992-10       Impact factor: 8.551

3.  Constitutive synthesis of a 92-kDa keratinocyte-derived type IV collagenase is enhanced by type I collagen and decreased by type IV collagen matrices.

Authors:  Y Sarret; D T Woodley; G S Goldberg; A Kronberger; K C Wynn
Journal:  J Invest Dermatol       Date:  1992-12       Impact factor: 8.551

4.  Dynamics of the cellular and humoral components of the inflammatory response elicited in skin blisters in humans.

Authors:  D B Kuhns; E DeCarlo; D M Hawk; J I Gallin
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

5.  Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas.

Authors:  S McDonnell; M Navre; R J Coffey; L M Matrisian
Journal:  Mol Carcinog       Date:  1991       Impact factor: 4.784

6.  The matrix metalloprotease matrilysin (PUMP) is expressed in developing human mononuclear phagocytes.

Authors:  D F Busiek; F P Ross; S McDonnell; G Murphy; L M Matrisian; H G Welgus
Journal:  J Biol Chem       Date:  1992-05-05       Impact factor: 5.157

7.  cDNA cloning of a novel human ubiquitin carrier protein. An antigenic domain specifically recognized by endemic pemphigus foliaceus autoantibodies is encoded in a secondary reading frame of this human epidermal transcript.

Authors:  Z Liu; L A Diaz; A L Haas; G J Giudice
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

8.  Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma.

Authors:  U K Saarialho-Kere; E S Chang; H G Welgus; W C Parks
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

9.  Cytoplasmic domain of the 180-kD bullous pemphigoid antigen, a hemidesmosomal component: molecular and cell biologic characterization.

Authors:  S B Hopkinson; K S Riddelle; J C Jones
Journal:  J Invest Dermatol       Date:  1992-09       Impact factor: 8.551

10.  Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin.

Authors:  G I Goldberg; A Strongin; I E Collier; L T Genrich; B L Marmer
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

View more
  45 in total

1.  Immunohistochemical localisation of the matrix metalloproteinases MMP-3 and MMP-9 within the airways in asthma.

Authors:  B Dahlen; J Shute; P Howarth
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

Review 2.  Autoimmune subepidermal bullous skin diseases: the impact of recent findings for the dermatopathologist.

Authors:  Roberto Verdolini; Rino Cerio
Journal:  Virchows Arch       Date:  2003-06-11       Impact factor: 4.064

Review 3.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Inhibition of gelatinase activity in human airway epithelial cells and fibroblasts by dexamethasone and beclomethasone.

Authors:  J E Carver; W A Galloway; C Robinson
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

5.  Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins.

Authors:  L Borrego; B Maynard; E A Peterson; T George; L Iglesias; M S Peters; W Newman; G J Gleich; K M Leiferman
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

6.  Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury.

Authors:  M E Fini; W C Parks; W B Rinehart; M T Girard; M Matsubara; J R Cook; J A West-Mays; P M Sadow; R E Burgeson; J J Jeffrey; M B Raizman; R R Krueger; J D Zieske
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

Review 7.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

8.  Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid.

Authors:  C Günther; G Wozel; M Meurer; C Pfeiffer
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

9.  The role of complement in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; S J Swartz; J A Fairley; G O Till; J L Troy; L A Diaz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy.

Authors:  Michelle Wehling-Henricks; Maria C Jordan; Tomomi Gotoh; Wayne W Grody; Kenneth P Roos; James G Tidball
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.